


### Quarterly performance



Source: Capital IQ

### Commentary

The ASX200 Healthcare Index was down 0.4% in the last quarter, under-performing the broader market.

Drivers of the Index include CSL trading near 3-month lows despite reaffirming FY25 guidance, the bidding war between Genesis Capital and Crescent Capital over Pacific Smiles (ASX:PSQ), the dentistry group, and the sell down of Crescent Capital's 30% holding of Australian Clinical Labs (ASX: ACL).

Healthcare M&A remains selective with financial sponsors and strategics focusing on navigating rising costs and ensuring effective capital allocation.

### Quarterly M&A & other news

Date	Description
30-Sep-24	<b>Pacific Smiles' Board (ASX:PSQ)</b> expected to reject Genesis Capital's bid. The Board is backed by two major shareholders including a co-founder and MA Asset Management that hold together 23.3% of the register
22-Sep-24	Affinity Equity, Asian buyout group will acquire <b>Lumus Imaging</b> from Healius pathology (ASX:HLS) for a price over \$900m
16-Sep-24	<b>Pacific Smiles (ASX:PSQ)</b> CEO Andrew Vidley and other executives resigned after investors voted against the Crescent Capital offer of \$327m at the scheme meeting. Genesis Capital lodged an improved off-market takeover offer of \$1.90 per share including cash and scrip
11-Sep-24	Crescent Capital traded their 30.1% ownership (60.8m shares) of <b>Australian Clinical Labs (ASX:ACL)</b> at \$3.20 per share. Crescent floated ACL at \$4.00 per share in 2021
1-Aug-24	Genesis Capital bid \$1.90 per share offer for <b>Pacific Smiles (ASX:PSQ)</b> , that is 1 cent lower than Crescent's offer although deemed superior by the Board as existing shareholders can roll their shares. Crescent increased its bid to \$2.05 per share
23-Jul-24	Crescent Capital upped its \$1.90 per share offer for <b>Pacific Smiles (ASX:PSQ)</b> by 1 cent
22-Jul-24	<b>Anteris Technologies (ASX:AVR)</b> , the heart medtech of which L1 Capital owns 16.9%, launched a \$40m equity raise to fund development of its flagship DurAVR THV product that aims to mimic a healthy aortic valve
17-Jul-24	<b>Five Good Friends</b> , a technology-enabled home care business, has appointed Record Point to run a sale process after a period of strong revenue growth
17-Jul-24	UK private equity firm, Permira is looking to exit its radiology owned business, <b>I-MED</b> seeking a \$4bn valuation
17-Jul-24	Healius (ASX:HLS), the pathology giant to divest the radiology business, <b>Lumus Imaging</b> with offers received from TPG Capital, EQT and Affinity Equity Partners around the \$700m mark
14-Jul-24	Genesis Capital issued a note to the <b>Pacific Smiles' Board (ASX:PSQ)</b> that it intends to vote its 19.9% shareholding against Crescent Capital's bid in the upcoming scheme meeting
11-Jul-24	<b>Pacific Smiles (ASX:PSQ)</b> has an offer from Crescent Capital for \$303m (\$1.90 cash bid), with a scheme meeting booked for 1-Aug. There is a competing offer from Genesis Capital of \$279m bid after securing a 19.9% stake through an equity derivative transaction in Dec-23
2-Jul-24	In-home care provider Silverchain acquired sponsor backed <b>KinCare</b> , another in-home aged care provider to expand its operations to the east coast resulting in Silverchain Group becoming the third largest home care provider
1-Jul-24	<b>Opal HealthCare</b> , aged care operator's current investors Singapore's GK Goh Holdings and AMP Capital funds are testing the market with AMP looking to cash out

Sources: Capital IQ, Mergermarket, press reports, AFR

## Largest 40 ASX-listed healthcare companies by market capitalisation (September 2024)

Company	Market capitalisation (A\$m)	Share price (A\$)	Share price performance (%)			Premium / (discount) to 52 week (%)		Premium / (discount) to VWAP (%)			Multiples (FY24F) <sup>(1)</sup>		
			Last quarter	Year-to-date	Last 12 months	High	Low	1 month	3 months	6 months	EV/Revenue	EV/EBITDA	P/E
1 CSL	138,619	286.28	(3.0%)	(0.1%)	14.1%	(9%)	25%	(3%)	(5%)	(2%)	7.1x	3.5x	35.0x
2 Pro Medicus	18,627	178.25	24%	86%	114%	-	140%	7%	23%	37%	n.m.	0.4x	n.m.
3 Cochlear	18,470	282.09	(15%)	(6%)	10%	(19%)	19%	(1%)	(8%)	(10%)	8.1x	0.4x	51.8x
4 Sonic Healthcare	13,076	27.23	4%	(15%)	(9%)	(16%)	15%	1%	1%	3%	1.9x	0.4x	25.6x
5 Ramsay Health Care	9,541	41.62	(12%)	(21%)	(20%)	(27%)	8%	0%	(6%)	(11%)	1.2x	0.5x	10.7x
6 Telix Pharmaceuticals	6,938	20.73	11%	106%	82%	(1%)	153%	9%	9%	17%	10.8x	0.2x	n.m.
7 Ansell	4,602	31.81	20%	26%	44%	(1%)	51%	3%	11%	18%	1.9x	0.1x	40.1x
8 Clarity Pharma	2,649	8.38	55%	341%	616%	(7%)	759%	2%	18%	40%	n.m.	0.1x	n.m.
9 Sigma Healthcare	2,263	1.44	13%	43%	109%	(3%)	129%	5%	10%	13%	0.6x	0.0x	n.m.
10 Neuren	1,935	15.14	(29%)	(39%)	37%	(42%)	51%	8%	(7%)	(17%)	9.7x	0.0x	16.2x
11 Regis Healthcare	1,865	6.19	42%	90%	129%	(3%)	159%	9%	23%	36%	1.8x	0.0x	n.m.
12 PolyNovo	1,803	2.61	7%	58%	100%	(6%)	138%	6%	5%	11%	17.2x	0.0x	n.m.
13 Healius	1,253	1.73	15%	6%	(25%)	(26%)	60%	2%	9%	20%	1.6x	0.1x	n.m.
14 Nanosonics	1,118	3.69	23%	(16%)	(13%)	(22%)	42%	4%	14%	20%	5.9x	0.0x	86.2x
15 Paragon Care	737	0.45	1%	n.a.	n.a.	(11%)	19%	6%	3%	4%	0.3x	0.0x	87.9x
16 Australian Clinical Labs	735	3.67	46%	27%	29%	(2%)	71%	11%	21%	26%	1.5x	0.0x	30.7x
17 Botanix Pharma	735	0.41	17%	113%	238%	(9%)	238%	1%	9%	19%	n.m.	0.0x	n.m.
18 Integral Diagnostics	695	2.97	11%	56%	3%	(1%)	81%	11%	15%	17%	2.2x	0.0x	n.m.
19 Monash IVF	477	1.23	(5%)	(6%)	(3%)	(20%)	9%	4%	(4%)	(8%)	2.4x	0.0x	n.m.
20 Capital Health	389	0.37	16%	55%	74%	(3%)	97%	9%	16%	28%	2.2x	0.0x	n.m.
21 Mayne Pharma	372	4.59	(3%)	(25%)	41%	(38%)	67%	(2%)	2%	(13%)	0.7x	0.0x	n.m.
22 EBR Systems	317	0.87	(17%)	43%	27%	(30%)	63%	(2%)	(10%)	(11%)	n.m.	0.0x	n.m.
23 Pacific Smiles	288	1.81	(5%)	24%	28%	(12%)	105%	(1%)	(3%)	(3%)	1.9x	0.0x	35.8x
24 4DMedical	277	0.68	30%	(6%)	50%	(39%)	65%	20%	28%	20%	n.m.	0.0x	n.m.
25 Anteris Technologies	258	12.20	(33%)	(36%)	(40%)	(49%)	31%	5%	(9%)	(20%)	47.8x	0.0x	n.m.
26 MedAdvisor	234	0.43	(15%)	98%	85%	(28%)	166%	14%	(8%)	(2%)	1.9x	0.0x	n.m.
27 Oneview Healthcare	222	0.33	(18%)	38%	32%	(22%)	78%	(2%)	(11%)	(5%)	12.0x	0.0x	n.m.
28 Cogstate	179	1.04	(8%)	(28%)	(32%)	(35%)	30%	19%	3%	(2%)	2.1x	0.0x	21.9x
29 EMVision Medical Devices	174	2.03	(6%)	20%	19%	(25%)	40%	(2%)	(0%)	(2%)	14.1x	0.0x	n.m.
30 Cyclopharm	169	1.52	(10%)	(21%)	(46%)	(52%)	13%	4%	4%	(3%)	5.3x	0.0x	n.m.
31 Arovela Therapeutics	163	0.16	11%	35%	128%	(16%)	150%	2%	1%	15%	n.m.	0.0x	n.m.
32 Optiscan Imaging	163	0.20	(17%)	132%	167%	(25%)	175%	14%	(8%)	17%	n.m.	0.0x	n.m.
33 Imricor Medical Systems	151	0.56	6%	(2%)	11%	(15%)	37%	4%	1%	9%	n.m.	0.0x	n.m.
34 Mach7 Technologies	134	0.56	(13%)	(30%)	(30%)	(31%)	7%	3%	(6%)	(12%)	3.7x	0.0x	n.m.
35 Vita Life Sciences	128	2.23	(2%)	25%	33%	(11%)	39%	(1%)	(1%)	4%	2.7x	0.0x	28.2x
36 Recce Pharma	124	0.54	(11%)	-	10%	(23%)	30%	4%	11%	5%	25.9x	0.0x	n.m.
37 ImpediMed	113	0.06	(22%)	(61%)	(68%)	(68%)	33%	13%	0%	(14%)	8.7x	0.0x	n.m.
38 SDI	111	0.93	18%	28%	16%	(5%)	31%	1%	4%	8%	1.2x	0.0x	10.6x
39 Percheron Therapeutics	95	0.11	24%	78%	54%	(9%)	102%	9%	23%	29%	27.9x	0.0x	n.m.
40 Austco Healthcare	93	0.26	42%	28%	34%	-	50%	8%	12%	18%	1.4x	0.0x	13.1x
<b>Average</b>	<b>5,757</b>		<b>5%</b>	<b>32%</b>	<b>53%</b>	<b>(19%)</b>	<b>89%</b>	<b>5%</b>	<b>5%</b>	<b>8%</b>	<b>7.3x</b>	<b>0.1x</b>	<b>35.3x</b>

## Top 10 best performers in the last quarter<sup>(2)</sup>

Company	Market capitalisation (A\$m)	Share price (A\$)	Share price performance (%)			Premium / (discount) to 52 week (%)		Premium / (discount) to VWAP (%)			Multiples (FY24F) <sup>(1)</sup>		
			Last quarter	Year-to-date	Last 12 months	High	Low	1 month	3 months	6 months	EV/Revenue	EV/EBITDA	P/E
1 Syntata Ltd	59	0.04	79%	115%	30%	(14%)	207%	n.a.	n.a.	n.a.	9.7x	0.0x	n.m.
2 SomnoMed	86	0.40	58%	(20%)	(43%)	(44%)	111%	(6%)	11%	60%	0.8x	0.0x	n.m.
3 Clarity Pharma	2,649	8.38	55%	341%	616%	(7%)	759%	2%	18%	40%	n.m.	0.1x	n.m.
4 Australian Clinical Labs	735	3.67	46%	27%	29%	(2%)	71%	11%	21%	26%	1.5x	0.0x	30.7x
5 Regis Healthcare	1,865	6.19	42%	90%	129%	(3%)	159%	9%	23%	36%	1.8x	0.0x	n.m.
6 Austco Healthcare	93	0.26	42%	28%	34%	-	50%	8%	12%	18%	1.4x	0.0x	13.1x
7 Beamtree	91	0.32	37%	34%	40%	(17%)	91%	1%	10%	25%	3.1x	0.0x	n.m.
8 4DMedical	277	0.68	30%	(6%)	50%	(39%)	65%	20%	28%	20%	n.m.	0.0x	n.m.
9 Alcidian	83	0.06	29%	(17%)	(44%)	(48%)	55%	1%	(7%)	1%	2.0x	0.0x	n.m.
10 Pro Medicus	18,627	178.25	24%	86%	114%	-	140%	7%	23%	37%	n.m.	0.4x	n.m.
<b>Average</b>	<b>2,457</b>		<b>44%</b>	<b>68%</b>	<b>96%</b>	<b>(17%)</b>	<b>171%</b>	<b>6%</b>	<b>15%</b>	<b>29%</b>	<b>2.9x</b>	<b>0.1x</b>	<b>21.9x</b>

## Top 10 worst performers in the last quarter<sup>(2)</sup>

Company	Market capitalisation (A\$m)	Share price (A\$)	Share price performance (%)			Premium / (discount) to 52 week (%)		Premium / (discount) to VWAP (%)			Multiples (FY24F) <sup>(1)</sup>		
			Last quarter	Year-to-date	Last 12 months	High	Low	1 month	3 months	6 months	EV/Revenue	EV/EBITDA	P/E
1 Anteris Technologies	258	12.20	(33%)	(36%)	(40%)	(49%)	31%	5%	(9%)	(20%)	47.8x	0.0x	n.m.
2 Neuren	1,935	15.14	(29%)	(39%)	37%	(42%)	51%	8%	(7%)	(17%)	9.7x	0.0x	16.2x
3 ImpediMed	113	0.06	(22%)	(61%)	(68%)	(68%)	33%	13%	0%	(14%)	8.7x	0.0x	n.m.
4 Next Science	56	0.19	(19%)	(44%)	(56%)	(62%)	6%	(5%)	(18%)	(29%)	1.4x	0.0x	n.m.
5 Oneview Healthcare	222	0.33	(18%)	38%	32%	(22%)	78%	(2%)	(11%)	(5%)	12.0x	0.0x	n.m.
6 EBR Systems	317	0.87	(17%)	43%	27%	(30%)	63%	(2%)	(10%)	(11%)	n.m.	0.0x	n.m.
7 Optiscan Imaging	163	0.20	(17%)	132%	167%	(25%)	175%	14%	(8%)	17%	n.m.	0.0x	n.m.
8 Cochlear	18,470	282.09	(15%)	(6%)	10%	(19%)	19%	(1%)	(8%)	(10%)	8.1x	0.4x	51.8x
9 MedAdvisor	234	0.43	(15%)	98%	85%	(28%)	166%	14%	(8%)	(2%)	1.9x	0.0x	n.m.
10 Neurotech International	62	0.06	(14%)	(13%)	(10%)	(52%)	15%	(9%)	(18%)	(25%)	15.9x	0.0x	n.m.
<b>Average</b>	<b>2,183</b>		<b>(20%)</b>	<b>11%</b>	<b>18%</b>	<b>(40%)</b>	<b>64%</b>	<b>4%</b>	<b>(10%)</b>	<b>(11%)</b>	<b>13.2x</b>	<b>0.0x</b>	<b>34.0x</b>

Source: Capital IQ as at 30 September 2024

Notes: (1) Calendarised to June year end. EV/EBITDA multiples are considered 'n.m.' if they are ≥50x. P/E multiples are considered 'n.m.' if they are ≥100x; (2) Top 10 best and worst performers are based on companies with a minimum market capitalisation of A\$50 million and have traded for the full quarter.